These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 36358960)

  • 1. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors.
    Mahmoud MA; Mohammed AF; Salem OIA; Almutairi TM; Bräse S; Youssif BGM
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305856. PubMed ID: 38326989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
    Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
    Molecules; 2023 May; 28(10):. PubMed ID: 37241785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational investigation of
    Yousaf MA; Anwer SA; Basheera S; Sivanandan S
    J Biomol Struct Dyn; 2024; 42(4):1901-1923. PubMed ID: 37154824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Indole-6-Carboxylic Acid Derivatives as Multi-Target Antiproliferative Agents: Synthesis, in Silico Studies, and Cytotoxicity Evaluation.
    Allawi MM; Mahmood AAR; Tahtamouni LH; AlSakhen MF; Kanaan SI; Saleh KM; Yasin SR
    Chem Biodivers; 2024 Feb; 21(2):e202301892. PubMed ID: 38145305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
    Alkamaly OM; Altwaijry N; Sabour R; Harras MF
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New benzimidazole-oxadiazole derivatives as potent VEGFR-2 inhibitors: Synthesis, anticancer evaluation, and docking study.
    Acar Çevik U; Celik I; Görgülü Ş; Şahin Inan ZD; Bostancı HE; Özkay Y; Kaplacıklı ZA
    Drug Dev Res; 2024 Jun; 85(4):e22218. PubMed ID: 38825827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
    Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
    Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel ureido benzothiophenes as dual VEGFR-2/EGFR anticancer agents.
    Eldehna WM; Al-Ansary GH; Al-Warhi T; Jaballah MY; Elaasser M; Rashed M
    Bioorg Chem; 2024 Feb; 143():107037. PubMed ID: 38134521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
    Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
    Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-synthesized anticancer theobromine derivatives targeting VEGFR-2:
    Dahab MA; Mahdy HA; Elkady H; Taghour MS; Elwan A; Elkady MA; Elsakka EGE; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
    J Biomol Struct Dyn; 2024 May; 42(8):4214-4233. PubMed ID: 37261471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodoquinazoline-derived VEGFR-2 and EGFR
    Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
    Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and activity relationship analysis of xanthones from mangosteen: Identifying garcinone E as a potent dual EGFR and VEGFR2 inhibitor.
    Li J; Nie X; Panthakarn Rangsinth ; Wu X; Zheng C; Cheng Y; Shiu PH; Li R; Lee SM; Fu C; Zhang J; Leung GP
    Phytomedicine; 2024 Jan; 122():155140. PubMed ID: 37939410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.